Cardiorentis enters into financing agreement with HealthCare Royalty Partners to fund Ularitide

17 September 2014

Privately-held Swiss pharma company Cardiorentis AG has entered into a 45 million-euro ($58.3 million) financing agreement with US-based health care investment firm HealthCare Royalty Partners.

The agreement will help fund Cardiorentis’ registration program for natriuretic peptide Ularitide to treat acute heart failure.

Johannes Holzmeister, chief executive and chief medical officer of Cardiorentis, said: "This is a pivotal time for our company. The team at HC Royalty understood the attractiveness of our program and our financing needs and then developed a structure that would give us a high degree of flexibility but also a sizeable amount of capital to complete our pivotal Phase III trial for Ularitide. We believe we have the financial resources in place to execute on our business strategy to introduce the first therapy with proven outcome benefits for patients with acute heart failure.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK